Boston, MANCT05079282Now EnrollingIRB Ready

Relapsed or Refractory T Cell Lymphoma Clinical Trial in Boston, MA

Access cutting-edge relapsed or refractory t cell lymphoma treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Ono Pharmaceutical Co., Ltd.

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access relapsed or refractory t cell lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed or refractory t cell lymphoma treatment provided free

Apply for This Boston Location

Check if you qualify for this relapsed or refractory t cell lymphoma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Relapsed or Refractory T Cell Lymphoma Study in Boston

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

Sponsor: Ono Pharmaceutical Co., Ltd.

Who Can Participate

Inclusion Criteria

Patients aged ≥ 18 years at time of screening
Written informed consent by the patient or the patients' legally authorized representative prior to screening
Patients with histologically or cytologically confirmed diagnosis of one of the following subtypes of T-cell lymphoma:
Peripheral T-cell lymphoma (PTCL): Angioimmunoblastic T-cell lymphoma (AITL), PTCL, not otherwise specified (PTCL-NOS), nodal PTCL with T-follicular helper (TFH) and follicular T-cell lymphoma (FTCL)
Cutaneous T-cell lymphoma (CTCL) (stages II-B, III, and IV): Mycosis fungoides (MF) and Sezary syndrome (SS)
Patients must have received at least 2 prior systemic therapies
Patients with PTCL must have at least 1 measurable lesion (Cheson BD, 2014)
Patients with CTCL must have assessable disease by response criteria for CTCL (Olsen EA, 2011)
Eastern Cooperative Oncology Group Performance Status (ECOG PS) = 0-2
Life expectancy of at least 3 months
Adequate bone marrow, renal and hepatic functions

Exclusion Criteria

Patients with central nervous system (CNS) involvement
Patients with Adult T-cell leukemia/lymphoma (ATLL)
Prior allogeneic stem cell transplant
Prior treatment with ONO-4685, anti-PD-1, anti-PD-L1, anticytotoxic T lymphocyte associated protein 4 (CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Prior allogeneic and autologous chimeric antigen receptor (CAR) T-cell therapy
Patients with malignancies (other than T-cell lymphoma) except for completely resected basal cell carcinoma, stage I squamous cell carcinoma, carcinoma in situ, or any other malignancies that has not relapsed for at least 2 years
History of severe allergy or hypersensitivity to any monoclonal antibodies, other therapeutic proteins or corticosteroid (e.g., dexamethasone)
History of infection with Mycobacterium tuberculosis within 2 years prior to the first dose of study treatment
Patients with systemic and active infection including human immunodeficiency virus (HIV), hepatitis B or C virus infection
Patients not recovered to Grade 1 or stabilized from the adverse effects (excluding alopecia) of any prior therapy for their malignancies
Women who are pregnant or lactating

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT05079282) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed or Refractory T Cell Lymphoma Treatment Options in Boston, MA

If you're searching for relapsed or refractory t cell lymphoma treatment options in Boston, MA, this clinical trial (NCT05079282) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed or refractory t cell lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed or refractory t cell lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Boston, MA

See all lymphoma clinical trials recruiting in Boston — not just this study.

Browse Lymphoma Trials in Boston →

Browse More Trials by Condition

Lymphoma TrialsRheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsPulmonary Hypertension TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA